On October 29, 2024, ZyVersa Therapeutics, Inc., a biopharmaceutical company, held its annual stockholders meeting where several key decisions were made. The stockholders approved an amendment and restatement of the company's 2022 Omnibus Equity Incentive Plan, increasing the number of shares reserved for issuance by 150,000 to a total of 181,795 shares. Additionally, the election of Min Chul Park, Ph.D. as a Class II director for a three-year term was confirmed with 183,493 votes in favor. Marcum LLP was ratified as the company's independent registered public accounting firm for the fiscal year ending December 31, 2024. Furthermore, the issuance of up to 478,600 shares of common stock upon the exercise of certain warrants was approved in accordance with Nasdaq Listing Rule 5635(d). The meeting saw a quorum with proxies representing approximately 43% of the outstanding shares entitled to vote.

On October 29, 2024, ZyVersa Therapeutics, Inc., a biopharmaceutical company, held its annual stockholders meeting where several key decisions were made. The stockholders approved an amendment and restatement of the company's 2022 Omnibus Equity Incentive Plan, increasing the number of shares reserved for issuance by 150,000 to a total of 181,795 shares. Additionally, the election of Min Chul Park, Ph.D. as a Class II director for a three-year term was confirmed with 183,493 votes in favor. Marcum LLP was ratified as the company's independent registered public accounting firm for the fiscal year ending December 31, 2024. Furthermore, the issuance of up to 478,600 shares of common stock upon the exercise of certain warrants was approved in accordance with Nasdaq Listing Rule 5635(d). The meeting saw a quorum with proxies representing approximately 43% of the outstanding shares entitled to vote.